Curis (NASDAQ:CRIS) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Curis (NASDAQ:CRIS) in a research report released on Friday,Benzinga reports. The firm currently has a $20.00 target price on the biotechnology company’s stock.

Curis Price Performance

Shares of NASDAQ:CRIS opened at $3.95 on Friday. The stock has a market capitalization of $23.62 million, a P/E ratio of -0.51 and a beta of 3.35. The business has a 50-day moving average of $5.01 and a two-hundred day moving average of $7.06. Curis has a fifty-two week low of $3.51 and a fifty-two week high of $17.49.

Hedge Funds Weigh In On Curis

A number of institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. grew its position in Curis by 4.8% in the 1st quarter. Vanguard Group Inc. now owns 218,573 shares of the biotechnology company’s stock worth $2,376,000 after purchasing an additional 10,097 shares during the last quarter. Point72 Asset Management L.P. lifted its stake in shares of Curis by 795.5% in the second quarter. Point72 Asset Management L.P. now owns 108,356 shares of the biotechnology company’s stock valued at $748,000 after buying an additional 96,256 shares during the period. Focused Wealth Management Inc grew its position in Curis by 63.1% during the third quarter. Focused Wealth Management Inc now owns 54,066 shares of the biotechnology company’s stock worth $291,000 after buying an additional 20,908 shares in the last quarter. Finally, CM Management LLC grew its position in Curis by 380.0% during the first quarter. CM Management LLC now owns 120,000 shares of the biotechnology company’s stock worth $1,304,000 after buying an additional 95,000 shares in the last quarter. 29.97% of the stock is currently owned by institutional investors.

About Curis

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.